<PAGE>
FORM 10-C
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report by issuer of securities quoted on The Nasdaq Stock Market(SM), filed
pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and Rule
13a-17 or 15d-17 thereunder.
Carrington Laboratories, Inc.
------------------------------------------------------------------------------
Exact name of issuer, as specified in charter
2001 Walnut Hill Lane, Irving, TX 75038
------------------------------------------------------------------------------
Address of principal executive offices
(214) 518-1300
------------------------------------------------------------------------------
Issuer's telephone number (including area code)
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of five percent or more in the
number of shares outstanding:
1. Title of security
Common Stock, $.01 par value
-------------------------------------------------------------------------------
2. Number of shares outstanding before the change
7,735,217
-------------------------------------------------------------------------------
3. Number of shares outstanding after the change
8,269,937
-------------------------------------------------------------------------------
4. Effective date of change
August 18, 1995
-------------------------------------------------------------------------------
5. Method of change
Issuance of a total of 458,970 shares upon exercising of outstanding
stock options and the issuance of a total of 75,750 shares upon
exercising of outstanding warrants.
-------------------------------------------------------------------------------
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
-------------------------------------------------------------------------------
Give brief description of transaction
-------------------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
-------------------------------------------------------------------------------
2. Name after change
-------------------------------------------------------------------------------
3. Effective date of charter amendment changing name
-------------------------------------------------------------------------------
4. Date of shareholder approval of change, if required
-------------------------------------------------------------------------------
Carlton I. Turner
President and Chief Executive Officer
8/21/95 Carrington Laboratories, Inc.
-------------------------------------------------------------------------------
DATE OFFICER'S SIGNATURE AND TITLE
